VXRT: Positive safety data, BARDA funding, and cash runway into Q2 2027 amid lower revenue
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw positive safety data from the COVID-19 oral pill vaccine trial and additional BARDA funding, with revenue declining year-over-year and a net loss of $13.5M. Cash runway extends into Q2 2027, and topline efficacy data is expected in the first half of 2027.Original document: Vaxart, Inc. [VXRT] SEC 8-K Current Report — Aug. 7 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw positive safety data from the COVID-19 oral pill vaccine trial and additional BARDA funding, with revenue declining year-over-year and a net loss of $13.5M. Cash runway extends into Q2 2027, and topline efficacy data is expected in the first half of 2027.
Original document: Vaxart, Inc. [VXRT] SEC 8-K Current Report — Aug. 7 2026